---
title: "Kazia Therapeutics Limited (KZIA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KZIA.US.md"
symbol: "KZIA.US"
name: "Kazia Therapeutics Limited"
industry: "Biotechnology"
datetime: "2026-06-13T14:58:59.408Z"
locales:
  - [en](https://longbridge.com/en/quote/KZIA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KZIA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KZIA.US.md)
---

# Kazia Therapeutics Limited (KZIA.US)

## Company Overview

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.kaziatherapeutics.com](https://www.kaziatherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:12.000Z

**Overall: D (0.67)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 264 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -24.58% |  |
| Net Profit YoY | 20.19% |  |
| P/B Ratio | 5.20 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 161877951.48 |  |
| Revenue | 1242616.50 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -106.90% | E |
| Profit Margin | -1200.90% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -24.58% | E |
| Net Profit YoY | 20.19% | B |
| Total Assets YoY | 327.26% | A |
| Net Assets YoY | 1413.37% | A |
| Cash Flow Margin | 63.15% | C |
| OCF YoY | -24.58% | E |
| Turnover | 0.04 | E |
| Gearing Ratio | 34.66% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Kazia Therapeutics Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-24.58%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "20.19%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.20",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "161877951.48",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1242616.50",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-106.90%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1200.90%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-24.58%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "20.19%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "327.26%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "1413.37%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "63.15%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-24.58%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.04",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.66%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.85 | 458/390 | - | - | - |
| PB | 5.20 | 331/390 | 4.88 | 4.31 | 3.28 |
| PS (TTM) | 130.27 | 262/390 | 81.45 | 15.46 | 5.26 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-11T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 50% |
| Overweight | 2 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 14.28 |
| Highest Target | 25.05 |
| Lowest Target | 18.48 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KZIA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KZIA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KZIA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KZIA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**